Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

A supplemental new drug application has been submitted for abiraterone acetate (Zytiga) in combination with prednisone and androgen deprivation therapy (ADT) for high-risk patients with metastatic hormone-naïve prostate cancer (HNPC) or newly-diagnosed metastatic hormone-sensitive prostate cancer (HSPC), according to a statement from the company developing therapy, Janssen Biotech.

Read more.

source: OncLive